PHARMACOKINETICS AND CLEARANCE OF CIPROFLOXACIN AND AMIKACIN DURING CONTINUOUS HEMODIALYSIS

被引:0
|
作者
COTERA, A
AGUILA, R
GAETE, L
SAFFIE, A
LORCA, E
THAMBO, S
机构
[1] UNIV CHILE,HOSP JOSE JOAQUIN AGUIRRE,FAC MED,UNIDAD PACIENTES CRITICOS,SANTIAGO,CHILE
[2] UNIV CHILE,HOSP JOSE JOAQUIN AGUIRRE,FAC MED,CTR FARMACOL CLIN,SANTIAGO,CHILE
关键词
HEMODIALYSIS; CIPROFLOXACIN; AMIKACIN; PHARMACOLOGY; CLINICAL; KINETICS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We studied the pharmacokinetic and clearance of a 200 mg ciprofloxacin and a 500 mg amikacin intravenous dose during 5 continuous hemodialyses procedures in 5 patients with acute oliguric renal failure. Hourly blood and ultrafiltrate drug concentrations were measured during 8 hours. Dialysate flux (Qd) was 16.6 ml/min during the first hours and 33.2 ml/mn thereafter. For each Qd, total ciprofloxacin clearance was 1.13+/-0.99 and 2.8+/-1.71 ml/min (p<0.0001), diffusive clearance was 0.96+/-0.87 and 2.47+/-1.56 ml/min (p<0.005) and convective clearance was 0.16+/-0.17 and 0.33+/-0.2 ml/min (p<0.05). Likewise, total amikacin clearance was 3.47+/-1.31 and 4.18+/-0.53 ml/min (p<0.001), diffusive clearance was 2.97+/-1.24 and 3.86+/-0.52 ml/min and convective clearance was 0.50+/-0.47 and 0.32+/-0.29 ml/min (p=NS). Protein binding was 84% for ciprofloxacin and 77% for amikacin. It is concluded that during continuous hemodialysis with cuprofan membrane, the main transport mechanism of ciprofloxacin and amikacin is diffusive. Very low amounts of ciprofloxacin are depurated by the dialyser. Likewise, the shortening of amikacin half life suggests the presence of other elimination pahway and the need to use supplementary doses every 24 hours.
引用
收藏
页码:742 / 748
页数:7
相关论文
共 50 条
  • [31] PHARMACOKINETICS OF FOSFOMYCIN DURING HEMODIALYSIS
    DALET, F
    BADE, G
    RODA, M
    CHEMOTHERAPY, 1977, 23 : 210 - 216
  • [32] MOXALACTAM PHARMACOKINETICS DURING HEMODIALYSIS
    ARONOFF, GR
    SLOAN, RS
    MONG, SA
    LUFT, FC
    KLEIT, SA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1981, 19 (04) : 575 - 577
  • [33] PHARMACOKINETICS OF MEZLOCILLIN DURING HEMODIALYSIS
    THORSTEINSSON, SB
    STEINGRIMSSON, O
    ASMUNDSSON, P
    BERGAN, T
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1981, : 59 - 63
  • [34] CEFSULODIN PHARMACOKINETICS DURING HEMODIALYSIS
    MATZKE, GR
    KEANE, WF
    TRANSACTIONS AMERICAN SOCIETY FOR ARTIFICIAL INTERNAL ORGANS, 1982, 28 : 324 - 328
  • [35] PHARMACOKINETICS OF ENOXACIN DURING HEMODIALYSIS
    DEUBER, HJ
    SCHULZ, W
    OHRISCH, G
    NIEREN-UND HOCHDRUCKKRANKHEITEN, 1993, 22 (08) : 369 - 374
  • [36] PHARMACOKINETICS OF CEFSULODIN DURING HEMODIALYSIS
    MATZKE, GR
    KEANE, WF
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1982, 16 (06): : 477 - 477
  • [37] GENTAMICIN PHARMACOKINETICS DURING HEMODIALYSIS
    CHRISTOPHER, TG
    KORN, D
    BLAIR, AD
    FOREY, AW
    ONEILL, MA
    CUTLER, RE
    KIDNEY INTERNATIONAL, 1974, 6 (01) : 38 - 44
  • [38] HEPARIN PHARMACOKINETICS DURING HEMODIALYSIS
    KANDROTAS, RJ
    GAL, P
    DOUGLAS, JB
    DETERDING, J
    THERAPEUTIC DRUG MONITORING, 1989, 11 (06) : 674 - 679
  • [39] PHARMACOKINETICS OF CIPROFLOXACIN IN THE ELDERLY - INCREASED ORAL BIOAVAILABILITY AND REDUCED RENAL CLEARANCE
    LJUNGBERG, B
    NILSSONEHLE, I
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1989, 8 (06) : 515 - 520
  • [40] Comparison of solute clearance during continuous hemofiltration, hemodiafiltration, and hemodialysis using a polysulfone hemofilter
    Reeves, John H.
    Butt, Warwick W.
    ASAIO Journal, 1995, 41 (01) : 100 - 104